Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $3.2 million.

  • Lifecore Biomedical's Free Cash Flow fell 45.86% to $3.2 million in Q2 2025 from the same period last year, while for May 2025 it was -$13.6 million, marking a year-over-year increase of 24.90%. This contributed to the annual value of -$13.6 million for FY2025, which is 24.90% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Free Cash Flow is $3.2 million, which was up 176.36% from -$4.3 million recorded in Q1 2025.
  • Lifecore Biomedical's 5-year Free Cash Flow high stood at $6.0 million for Q2 2024, and its period low was -$23.3 million during Q1 2022.
  • Over the past 3 years, Lifecore Biomedical's median Free Cash Flow value was -$6.0 million (recorded in 2024), while the average stood at -$6.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 658.64% in 2021, then skyrocketed by 163.62% in 2024.
  • Lifecore Biomedical's Free Cash Flow (Quarterly) stood at -$10.2 million in 2021, then spiked by 39.41% to -$6.2 million in 2022, then surged by 52.06% to -$3.0 million in 2023, then slumped by 188.60% to -$8.6 million in 2024, then tumbled by 45.86% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q2 2025, -$4.3 million for Q1 2025, and -$8.6 million during Q4 2024.